Status: Recruiting
A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the recommended phase 2 dose. In addition, the preliminary effects of QX1206 on antidiabetic activity and other metabolic parameters will also be evaluated.
Participants needed: 52
Trial details
Phase: Phase 1Age: 18-64Biological sex: AllType: InterventionalSponsor: 1Globe Health InstituteUpdated: Jan 13, 2025Locations: 1
Eligibility criteria
Signed written informed consent must be obtained and documented [+8]
Uncontrolled diabetes [+12]